![]() |
|
|
Vol. 288, Issue 2, 414-420, February 1999
-D-Glucuronide:
Effects of Dibromosulfophthalein on Membrane Transport and Aglycone
Formation1
Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, South Australia and Department of Clinical and Experimental Pharmacology, The University of Adelaide, Adelaide, South Australia (L.S., B.C.S.); and Centre for Pharmaceutical Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia (A.M.E., R.L.N.)
| |
Abstract |
|---|
|
|
|---|
The liver plays an important role in the disposition of acyl
glucuronides by determining their extent of formation, biliary excretion, and efflux into blood. Thus, both intrahepatic and extrahepatic exposure to these reactive polar conjugates depends on the
efficiency of hepatic transport mechanisms, which may be shared with
other nonbile acid organic anions. Using the isolated perfused rat
liver preparation, the hepatic disposition of the acyl glucuronide,
1-O-gemfibrozil-
-D-glucuronide, was
examined in the presence of the organic anion dibromosulfophthalein
(DBSP). Using a recirculating system, livers were perfused for 90 min with an erythrocyte-free perfusion medium containing 1% (w/v) albumin
and 1-O-gemfibrozil-
-D-glucuronide (3 µM) alone (n = 6) or with DBSP (200 µM,
n = 7). The glucuronide was avidly taken up by the
liver, excreted into bile, and hydrolyzed within the liver to its
aglycone, gemfibrozil. DBSP significantly (P < .05) lowered the conjugate's mean hepatic clearance (8.98-5.17
ml/min), intrinsic clearance (44.0-17.7 ml/min), and fraction
eliminated in bile (72.8-48.7% of the dose), while increasing
perfusate gemfibrozil concentrations (0.52-0.92 µM at 90 min).
Furthermore, DBSP significantly (P < .05) lowered
the ratio of intrahepatic to unbound perfusate concentrations of
1-O-gemfibrozil-
-D-glucuronide
(139.0-35.0) and showed a trend to lower the ratio of bile to
intrahepatic concentrations (111.3-76.2, P = .05).
Thus, the study demonstrated that DBSP inhibited both the sinusoidal
uptake and canalicular transport of
1-O-gemfibrozil-
-D-glucuronide,
suggesting that the hepatic membrane transport of acyl glucuronides is
carrier mediated and shared with other organic anions.
| |
Introduction |
|---|
|
|
|---|
Many
drugs, including nonsteroidal anti-inflammatory agents and fibrate
hypolipidemic agents, possess a carboxylic acid functional group and
are metabolized to acyl glucuronide conjugates. These conjugates are
chemically reactive and susceptible to nucleophilic attack. Depending
on the reacting nucleophilic species, substitution at the carbonyl
group may result in hydrolysis to regenerate the parent carboxylic
acid, formation of rearrangement isomers via migration of the parent
group from the 1-O-
-position of the glucuronic acid ring,
and formation of adducts via covalent binding to nucleophilic residues
on proteins (Spahn-Langguth and Benet, 1992
) and DNA (Sallustio et al.,
1997b
).
Acyl glucuronide conjugates are essentially fully ionized at
physiological pH and are highly polar (Vore, 1994
). Therefore, their
movement between their primary site of formation, hepatocytes, and
blood, bile, or extrahepatic tissues may be restricted by their limited
ability to passively diffuse across the membrane barriers that separate
these compartments. Moreover, their movement across these membranes may
involve carrier systems, the characteristics of which are poorly understood.
In vitro studies using isolated hepatocytes have shown that
bromosulfophthalein (BSP), bilirubin, and bilirubin monoglucuronide, but not the bile acid taurocholate, inhibit the cellular uptake of
preformed bilirubin diglucuronide (Adachi et al., 1991
). Studies using
canalicular membrane vesicles from TR
rats
(Nishida et al., 1992
), which retain normal bile acid transport (Kuipers et al., 1989
) but have genetically defective canalicular ATP-dependent transport of nonbile acid organic anions such as dibromosulfophthalein (DBSP) (Jansen et al., 1987
), have shown impaired
canalicular transport of bilirubin diglucuronide. Both the ATP- and
membrane potential-dependent canalicular transport of bilirubin
diglucuronide were inhibited by BSP (Nishida et al., 1992
). BSP and
DBSP are cholephilic dyes that are commonly used as markers for hepatic
sinusoidal and canalicular membrane transport systems of nonbile acid
organic anions. A study with nafenopin acyl glucuronide demonstrated
that its transport across the canalicular membrane in
TR
rats also was impaired (Jedlitschky et al.,
1994
). In addition, canalicular transport of nafenopin acyl glucuronide
in normal rats was ATP dependent and inhibited by the organic anions
cystenyl leukotriene and S-(2,4-dinitrophenyl)-glutathione
(DNP-SG) (Jedlitschky et al., 1994
). These studies suggest that the
carrier-mediated sinusoidal uptake and canalicular secretion of the
acyl glucuronides of bilirubin and nafenopin are shared with other
nonbile acid organic anions.
The acyl glucuronide
1-O-gemfibrozil-
-D-glucuronide (GG)
is a major metabolite of the fibrate hypolipidemic agent gemfibrozil (Curtis et al., 1985
; Knauf et al., 1990
). Previous studies have shown
that GG is efficiently excreted into the bile of rats (Curtis et al.,
1985
), and indirect evidence indicates its biliary excretion in humans
(Knauf et al., 1990
). Using the rat isolated perfused liver model, we
previously investigated the disposition of GG and demonstrated that it
undergoes avid hepatic uptake and biliary secretion and that the liver
is involved in the conversion of GG to its aglycone (Sallustio et al.,
1996
). The aim of the present study was to investigate the hepatic
disposition of preformed GG in the presence of a potentially competing
organic anion, DBSP, using the rat isolated perfused liver. By using
the intact liver, it was possible to investigate the effect of DBSP not
only on the movement of GG across hepatic membranes but also on the
extent of conversion of the conjugate to the aglycone.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Gemfibrozil,
-glucuronidase, sodium
taurocholate, phenylmethylsulfonyl fluoride, and
D-saccharic acid-1,4-lactone were purchased from Sigma
Chemical Co. (St. Louis, MO). GG was biosynthesized and purified as
previously described (Sallustio and Fairchild, 1995
) and stored at
20°C. Bovine serum albumin (Pentex, Fraction V) was purchased from
Miles Inc. (Kankakee, IL). DBSP was purchased from Societe d'Etutes et
de Reserches Biologiques (Paris, France). All other reagents were of
analytical grade.
Liver Perfusion.
The studies were approved by the animal
ethics committees of the Queen Elizabeth Hospital, the University of
Adelaide, and the University of South Australia. Male Sprague-Dawley
rats (250-350 g) were used, and livers were perfused in situ as
described previously (Sallustio et al., 1996
). Perfusions were
performed using erythrocyte-free Krebs-bicarbonate buffer (0.25 liters,
pH 7.4) supplemented with glucose (3 g/liter), sodium taurocholate (4.5 mg/liter), and albumin (1% w/v); gassed with humidified carbogen (5%
CO2/95% O2); and pumped
through the portal vein at a constant flow rate of 30 ml/min. In this
recirculating system, the hepatic outflow was returned to the perfusate
reservoir via a cannula inserted into the superior vena cava. The
common bile duct was cannulated to allow collection of bile, the flow
rate of which was determined gravimetrically assuming a specific
gravity of 1. Sodium taurocholate was continuously infused (7.74 mg/h)
into the perfusion medium to maintain adequate concentrations of the
bile acid to promote bile flow. The whole preparation was maintained at
37°C within a thermostatically controlled perfusion cabinet. The
viability of the isolated perfused liver was assessed by monitoring
oxygen consumption (>10 µmol/min), bile flow (>5 µl/min), percent
recovery of perfusate (>95%), and the gross appearance of the organ.
The livers were perfused for an initial equilibration period of 20 min
before the addition of GG to the perfusion medium in the reservoir.
20°C. At the end of each perfusion, the liver was blotted dry,
frozen, and stored at
80°C. On the next day, bile samples were
thawed and diluted (1:200) in 1.0 M glycine buffer (pH 3.0). The
diluted bile samples were stored at
20°C until analysis.
Protein Binding of Gemfibrozil and GG in Perfusate.
GG or
gemfibrozil was added to perfusion medium at 37°C to achieve
concentrations of 2 to 133 µM and 20 to 200 µM, respectively. Stock
solutions of GG and gemfibrozil were prepared in acetonitrile, and the
amount of acetonitrile added to the perfusate represented <2% of the
total final volume of perfusate. For displacement studies with DBSP,
the organic anion was added to the perfusate at a concentration of 200 µM, before the addition of either GG or gemfibrozil. The binding of
GG and gemfibrozil was determined at 37°C by rapid ultrafiltration of
1-ml aliquots, in duplicate, using a micropartition filter (Centrifree;
Amicon Corporation, Beverly, MA) centrifuged at 2000g for 15 min using an angled rotor. A 500-µl aliquot of ultrafiltrate was
immediately stabilized by the addition of 50 µl of 0.3 M phosphoric
acid and stored at
20°C until analysis. The fraction unbound (fu)
was calculated as the concentration ratio of the ultrafiltrate to the
unfiltered perfusion medium. Previous studies in this laboratory
(Sallustio et al., 1996
) have demonstrated that there was no
nonspecific binding of GG and gemfibrozil to the ultrafiltration equipment.
Analytical Methods.
Concentrations of GG, its rearrangement
isomers, and gemfibrozil in perfusion medium, bile, and ultrafiltrate
were determined by direct high performance liquid chromatography
analysis as described previously (Sallustio and Fairchild, 1995
). The
limits of quantification for GG and gemfibrozil were 0.06 and 0.08 µM, respectively. To determine intrahepatic concentrations of GG and
gemfibrozil, livers were thawed, weighed, and homogenized in 0.15 M
phosphate buffer (2 ml/g tissue) containing 2 mM phenylmethylsulfonyl
fluoride and 40 mM D-saccharic acid-1,4-lactone to prevent
degradation of GG during analysis (Ojingwa et al., 1994a
), and 0.5 ml
of the homogenate was assayed in four replicates. Calibration curves spanning a concentration range of 0.4 to 220 nmol/g liver (GG) and 8 to
320 nmol/g liver (gemfibrozil) were prepared by spiking liver
homogenates from drug-free perfused rat livers. Flurbiprofen (100 µl
of 2.5 mg/liter) was added as internal standard. Acetonitrile (1.3 ml)
was added to the liver homogenates (0.5 ml), and the samples were
vortexed and centrifuged (1000g for 15 min). The supernatant
was transferred to a clean tube, and 1.0 M glycine buffer (1 ml, pH
3.0) and ethyl acetate (4 ml) were added. Samples were gently mixed on
a horizontal shaker and centrifuged (1000g for 15 min). The
organic layer was dried in an evacuated centrifuge and the residue
reconstituted in high performance liquid chromatography mobile phase
(0.25 ml) before analysis (Sallustio and Fairchild, 1995
). Ratios of GG
concentrations in liver to perfusate (total and unbound) and bile to
liver were calculated at the 90-min time point. An assay for measuring
the extent of covalently bound adduct formation in the liver was used
as described previously (Sallustio and Foster, 1995
). The limit of
quantification for covalently bound gemfibrozil was 0.2 nmol/g liver.
DBSP did not interfere with the analysis of GG and gemfibrozil in
perfusate, bile, or liver.
Pharmacokinetic Analysis.
The
T1/2 of GG was determined by regression
analysis of the log concentration-versus-time profile, and the area
under the perfusate concentration versus time curve from 0 to 90 min
[AUC(0-90)] was calculated by the trapezoidal
method, and this was added to the extrapolated area to determine the
area under the curve to infinite time
[AUC(0-
)].
|
(1) |
|
(2) |
|
(3) |
Statistical Analysis. All values are presented as mean ± S.D. The nonparametric, unpaired Mann-Whitney U test (Prism 2.0; GraphPAD Software, San Diego, CA) was used to determine whether there were differences between the control and DBSP groups with respect to the pharmacokinetic parameters describing the disposition of GG and gemfibrozil and their respective concentrations in perfusate and bile at individual sampling times. Two-way analysis of variance (Prism 2.0) was used for the statistical analysis of bile flow rates, oxygen consumption rates, and protein-binding data. For all statistical tests, a P value of less than .05 was taken to represent significance.
| |
Results |
|---|
|
|
|---|
Protein Binding of GG and Gemfibrozil in Perfusate. Analysis of the ultrafiltrate samples from protein-binding experiments revealed minimal degradation of GG during ultrafiltration. Approximately 10% of the total ultrafiltrate glucuronide content was rearrangement isomers of GG, and this may have been partly due to minor contamination (~5%) of the biosynthetic sample of GG. No gemfibrozil was detected in any GG ultrafiltrate samples, suggesting negligible hydrolysis.
GG exhibited a moderate degree of binding to albumin, whereas gemfibrozil was more highly bound (Fig. 1). The binding of GG over the range of 2 to 133 µM was linear with a mean fu of 0.30 ± 0.01 (Fig. 1). In contrast, the binding of gemfibrozil was nonlinear over the range of 20 to 200 µM, with an fu of less than 0.05 (Fig. 1; P < .05). In the presence of 200 µM DBSP, the fu of GG was increased to 0.36 ± 0.03 (P < .05); however, DBSP did not alter the binding of gemfibrozil to albumin (Fig. 1).
|
Liver Perfusion Experiments. The viability of perfused livers was comparable between control and DBSP experiments. Throughout all perfusions, bile flow rate remained greater than 5 µl/min and did not change significantly over time (Fig. 2). Oxygen consumption, which was measured at the start and end of each perfusion, was greater than 10 µmol/min for both control and DBSP perfusions and did not change with time or between groups (Fig. 2).
|
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
Consistent with a previous report from our laboratory (Sallustio
et al., 1996
), the present study demonstrates that GG is avidly taken
up across the sinusoidal membrane into hepatocytes, wherein it is
either transported across the canalicular membrane into bile or
hydrolyzed to form its aglycone gemfibrozil. This study also confirms
that the hepatically generated gemfibrozil is not excreted into bile
but is subject to sinusoidal efflux into perfusate (Sallustio et al.,
1996
). An additional finding of the present study is the high
concentration gradients for GG between the liver and perfusate and
between bile and the liver. This is consistent with the concept that
the movement of GG from perfusate into bile is a two-step concentrative
process involving carrier-mediated systems at both the sinusoidal and
canalicular membranes of hepatocytes.
The organic anion DBSP was found to cause a significant reduction in the hepatic intrinsic clearance of GG, leading in turn to a reduction in hepatic clearance and extraction ratio and a significant prolongation of T1/2. The reduction in hepatic intrinsic clearance of GG could conceivably be due to inhibition of sinusoidal uptake into hepatocytes, metabolism, and/or the movement of GG into bile. A schematic diagram of the disposition of GG in the rat isolated perfused liver and the potential sites at which DBSP could influence the disposition of GG is shown in Fig. 6.
|
The observed reductions in CLint and biliary
excretion rate of GG in the presence of DBSP are unlikely to be due to
an inherent toxic effect of DBSP on the liver as bile flow rate and
hepatic oxygen consumption were unaffected by the addition of DBSP.
Other studies that have used DBSP in vivo (Javitt, 1964
; Klaassen and Plaa, 1968
; Dhumeaux et al., 1974
) or in the rat isolated perfused liver (Durham et al., 1985
) have not reported changes in hepatic viability after DBSP administration. In addition, the observed effects
of DBSP on the disposition of GG were unlikely to be due to altered
cellular metabolism or depletion of cosubstrates because DBSP is
excreted unchanged into bile (Javitt, 1964
; Klaassen and Plaa, 1968
).
Furthermore, as the study was carried out with preformed glucuronide
conjugate, a decrease in the glucuronidating capacity of the liver
would not have been expected to markedly alter the hepatic disposition
of the preformed conjugate. DBSP, however, is extensively bound to
albumin (98% bound) (Meijer et al., 1977
) and is a substrate for both
the sinusoidal and canalicular organic anion transporter systems (Oude
Elferink et al., 1995
). Therefore, to identify the mechanism by which
DBSP alters the disposition of GG, the potential competition for
perfusate albumin binding sites and hepatic transport systems should be considered.
Both GG and gemfibrozil were bound to albumin, consistent with many
findings for carboxylic acid drugs and their glucuronides such as
zomepirac (Ojingwa et al., 1994b
), tolmetin (Ojingwa et al., 1994b
),
ketoprofen (Hayball et al., 1992
), carprofen (Iwakawa et al., 1990
),
and fenoprofen (Bischer et al., 1995
). In the present study, it is
clear that gemfibrozil had a higher affinity for albumin than did its
glucuronide conjugate. Therefore, given the molar ratios of ligand to
binding protein, it is not unexpected that gemfibrozil exhibited
nonlinear binding to albumin. DBSP caused a significant increase in the
fu of GG but had no effect on the binding of gemfibrozil. The different
effects of DBSP on the binding of the two ligands to albumin are
consistent with the lower affinity of GG for albumin compared with that
of gemfibrozil. However, the result is also consistent with the
presence of different binding sites on albumin for gemfibrozil and its
glucuronide. Different binding sites on albumin have been reported for
carprofen enantiomers and their acyl glucuronides (Iwakawa et al.,
1990
), whereas fenoprofen (Bischer et al., 1995
), zomepirac (Ojingwa et
al., 1994b
), and tolmetin (Ojingwa et al., 1994b
) share common binding
sites with their respective acyl glucuronides.
With a hepatic extraction ratio of 0.3, GG may be classified as a low
clearance compound, and thus its hepatic clearance should be dependent
on fu and CLint (Wilkinson and Shand, 1975
). The 42% lower CL of GG is the combined result of an increase in fu counteracted by a larger decrease in CLint. As
discussed earlier, DBSP is unlikely to alter intrinsic metabolic
activity; therefore, the observed reduction in
CLint is likely to be due to an interaction with
DBSP at the level of hepatic membrane transport.
A number of carrier-mediated transport systems have been identified for
organic anions at both the sinusoidal and canalicular membranes of
hepatocytes. At the sinusoidal membrane, a sodium-dependent transport
system (Hagenbuch et al., 1990
) and a sodium-independent transport
system have been identified for the uptake of bile acids into the liver
(Jacquemin et al., 1994
), the latter system of which also mediates
uptake of nonbile acid organic anions such as DBSP and BSP (Oude
Elferink et al., 1995
). In addition, at least three other putative
carrier-proteins have been proposed to mediate the sinusoidal uptake of
nonbile acid organic anions, including DBSP, BSP, and bilirubin
(Groothuis and Meijer, 1996
). Little information is available on the
efflux of compounds from the liver across the sinusoidal membrane into
the systemic circulation. However, the inhibition of sinusoidal efflux
of morphine-3-glucuronide by probenecid (Evans et al., 1995
) and of
harmol sulfate by DBSP (De Vries et al., 1985
) indicates that
carrier-mediated efflux systems are present at the sinusoidal membrane.
Transporters at the canalicular membrane include an ATP-dependent bile
acid transporter and the ATP-dependent canalicular multispecific
organic anion transporter (rat cmoat or human cMOAT), which
exports nonbile acid organic anions such as cystenyl leukotriene, DBSP,
bilirubin glucuronide conjugates, and DNP-SG (Keppler and Arias, 1997
). As discussed earlier, the transport mechanisms for acyl glucuronides are poorly understood. Previous studies suggest that the transport mechanisms for acyl glucuronides at both the sinusoidal and canalicular membranes of hepatocytes may be shared with nonbile acid organic anions
(Adachi et al., 1991
; Jedlitschky et al., 1994
).
In the present study, the lower CLint and lower
biliary excretion rate of GG in the presence of DBSP may have been due
to inhibition of sinusoidal uptake of GG into the liver and/or
inhibition of canalicular transport into bile (Fig. 6). In the presence
of DBSP, the liver-to-perfusate and bile-to-liver concentration ratios of GG were lower, indicating that DBSP inhibited both sinusoidal uptake
and canalicular transport of GG. This is consistent with previous
reports that DBSP inhibited the sinusoidal uptake of DNP-SG (Hinchman
et al., 1993
), pravastatin (Yamazaki et al., 1996
), the glucuronide and
sulfate conjugates of E3040 (Takenaka et al., 1997
), and the
canalicular transport of lithocholic acid 3-O-glucuronide
(Kuipers et al., 1989
) and liquiritigenin (ether) glucuronides
(Shimamura et al., 1994
) into bile. DBSP may also have inhibited
sinusoidal efflux of GG (De Vries et al., 1985
); however, this effect
may have been masked by the significant inhibition of sinusoidal uptake.
It has previously been demonstrated that the liver is involved in the
hydrolysis of GG to gemfibrozil (Sallustio et al., 1996
). In the
present study, higher perfusate concentrations of gemfibrozil were
observed in the presence of DBSP, suggesting that a greater fraction of
the dose of GG was hydrolyzed within the liver (Fig. 5). In the absence
of an effect of DBSP on intrinsic cellular metabolism, this increase in
gemfibrozil concentrations may have arisen from inhibition of
canalicular transport of GG.
Reduced in vivo clearance of highly glucuronidated carboxylic acid
drugs has previously been demonstrated as a consequence of decreased
renal membrane transport of their acyl glucuronides (Meffin et al.,
1983b
). Reduced clofibric acid clearance in the presence of probenecid,
in rabbits and humans, has been suggested to be due to competitive
inhibition of the renal membrane transport of clofibric acid
glucuronide, leading to reduced renal clearance and increased systemic
hydrolysis to the aglycone (Meffin et al., 1983a
). The present study
shows that similar interactions between acyl glucuronides and organic
anions may occur at the level of the hepatic transport systems,
resulting in reduced hepatic clearance of the acyl glucuronide and
increased systemic concentrations of the aglycone.
Acyl glucuronides are known to form covalently bound adducts with liver
proteins (Hargus et al., 1994
; Ojingwa et al., 1994a
) As the major site
of acyl glucuronide formation, the liver is a target site for adduct
formation, and any factor that increases its exposure to acyl
glucuronides may also increase the extent of adduct formation. In the
present study, we were unable to detect any adduct formation, which is
consistent with GG being one of the least reactive acyl glucuronides
(Spahn-Langguth and Benet, 1992
; Sallustio et al., 1997a
).
In summary, the present study demonstrates that the hepatic membrane transport of the acyl glucuronide GG is carrier mediated and shared with other organic anions and that interactions at the level of hepatic sinusoidal and canalicular transport can lead to significant alterations in the hepatic disposition of acyl glucuronides. Furthermore, an indirect consequence of this interaction is the increased formation of the aglycone.
| |
Footnotes |
|---|
Accepted for publication August 7, 1998.
Received for publication March 6, 1998.
1 This study was supported in part by a University of South Australia Internal Research Development Grant and a National Health and Medical Research Foundation Grant. L.S. is funded by a Queen Elizabeth Hospital Postgraduate Research Scholarship.
Send reprint requests to: Dr. B.C. Sallustio, Department of Clinical Pharmacology, The Queen Elizabeth Hospital, 28 Woodville Rd. Woodville South 5011, South Australia.
| |
Abbreviations |
|---|
Agg(0-90), amount excreted in bile
over 90 min;
AUC(0-
), area under the perfusate
concentration versus time curve from 0 to infinity;
AUC(0-90), area under the perfusate concentration versus
time curve from 0 to 90 min;
Bgg, fraction cleared
unchanged by biliary excretion;
BSP, bromosulfophthalein;
CL, total
clearance;
CLint, intrinsic clearance;
D, dose;
DBSP, dibromosulfophthalein;
DNP-SG, S-(2,4-dinitrophenyl)-glutathione;
fu, fraction unbound in perfusate;
GG, 1-O-gemfibrozil-
-D-glucuronide.
| |
References |
|---|
|
|
|---|
treatment on the biliary transport maximum of dibromosulfophthalein, and the glucuronide conjugates of 5-phenyl-5-p-hydroxyphenyl(14C)hydantoin and (14C)morphine in the isolated perfused rat liver.
Drug Metab Dispos
10:
344-349[Abstract].
) with inherited conjugated hyperbilirubinemia.
J Clin Invest
90:
2130-2135.
acylglucuronide.
J Chromatogr
665:
345-353.
-D-glucuronide.
Drug Metab Dispos
25:
55-60
-acyl glucuronide: Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats.
Drug Metab Dispos
23:
892-899[Abstract].This article has been cited by other articles:
![]() |
Y. Shitara, M. Hirano, H. Sato, and Y. Sugiyama Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 228 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Sallustio and F. L. Holbrook In Vivo Perturbation of Rat Hepatocyte Canalicular Membrane Function by Diclofenac Drug Metab. Dispos., December 1, 2001; 29(12): 1535 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sabordo, B. C. Sallustio, A. M. Evans, and R. L. Nation Hepatic Disposition of the Acyl Glucuronide 1-O-Gemfibrozil-beta -D-glucuronide: Effects of Clofibric Acid, Acetaminophen, and Acetaminophen Glucuronide J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 44 - 50. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||